OU RUI Biotechnology

Ourui Biotech, also known as Ouroly, is a biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies. The company utilizes its proprietary technology platform to design Proteolysis Targeting Chimeras (PROTACs) and molecular glues aimed at previously "undruggable" protein targets. Their research is primarily focused on oncology and immunology, seeking to address unmet medical needs in drug-resistant cancers and chronic inflammatory conditions. Founded in 2021 and headquartered in the Suzhou BioBAY industrial park, Ourui Biotech has attracted significant investment from prominent venture capital firms to advance its early-stage pipeline. The company aims to leverage the ubiquitin-proteasome system to provide highly selective and potent therapeutic options for patients.